The Current Landscape Surrounding Adjuvant Therapy in Melanoma

Nikhil Khushalani, MD, provides a thorough exploration of the current treatment landscape in adjuvant therapy for melanoma, presenting insights into advancing strategies and developments in the field, while also discussing key findings from the CheckMate 238 and KEYNOTE-054 trials.

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

Now Viewing

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® discussion involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment provides an overview of the adjuvant therapy landscape for melanoma, focusing on stage III resected nodal disease. Dr Khushalani notes that adjuvant therapy has progressed from interferon to anti–CTLA-4 therapy with ipilimumab to now checkpoint inhibitors and BRAF/MEK (mitogen-activated extracellular signal regulated kinase) inhibitors.

The two main adjuvant therapy categories now are immune checkpoint inhibitor monotherapy (nivolumab or pembrolizumab) or BRAF/MEK inhibitor therapy for BRAF V600 mutant tumors. Both approaches improve relapse-free survival compared with placebo based on clinical trial data.

For BRAF V600–mutant resected stage III melanoma, the COMBI-AD trial showed improved relapse-free and overall survival with adjuvant dabrafenib/trametinib compared with placebo. Meanwhile, adjuvant ipilimumab plus nivolumab did not outperform nivolumab alone in patients with resected stage III disease.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.